State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
The Key Laboratory for Cell Proliferation and Regulation Biology of Ministry of Education, College of Life Sciences, Beijing Normal University, Beijing, China.
Front Immunol. 2022 Apr 7;13:844781. doi: 10.3389/fimmu.2022.844781. eCollection 2022.
Sepsis consists of life-threatening organ dysfunction resulting from a dysregulated response to infection. Recent studies have found that excessive neutrophil extracellular traps (NETs) contribute to the pathogenesis of sepsis, thereby increasing morbidity and mortality. Lysophosphatidic acid (LPA) is a small glycerophospholipid molecule that exerts multiple functions by binding to its receptors. Although LPA has been functionally identified to induce NETs, whether and how LPA receptors, especially lysophosphatidic acid receptor 3 (LPA), play a role in the development of sepsis has never been explored. A comprehensive understanding of the impact of LPA on sepsis is essential for the development of medical therapy. After intraperitoneal injection of lipopolysaccharide (LPS), mice showed a substantially higher mortality, more severe injury, and more fibrinogen content in the lungs than wild-type (WT) mice. The values of blood coagulation markers, plasma prothrombin time (PT) and fibrinogen (FIB), indicated that the mice underwent a severe coagulation process, which resulted in increased thrombosis. The levels of NETs in mice were higher than those in WT mice after LPS injection. The mortality rate and degree of lung damage in mice with sepsis were significantly reduced after the destruction of NETs by DNaseI treatment. Furthermore, experiments with co-cultured monocytes and neutrophils demonstrated that monocytes from mice promoted the formation of NETs, suggesting that LPA acting on monocytes inhibits the formation of NETs and plays a protective role in sepsis. Mechanistically, we found that the amount of CD14, an LPS co-receptor, expressed by monocytes in mice was significantly elevated after LPS administration, and the MyD88-p65-NFκB signaling axis, downstream of toll-like receptor 4 signaling, in monocytes was overactivated. Finally, after an injection of the LPA agonist (2S)-1-oleoyl-2-methylglycero-3-phosphothionate (OMPT), the survival rate of mice with sepsis was improved, organ damage was reduced, and the production of NETs was decreased. This suggested the possible translational value and application prospects of (2S)-OMPT in the treatment of sepsis. Our study confirms an important protective role of LPA in curbing the development of sepsis by suppressing NETs production and thrombosis and provides new ideas for sepsis treatment strategies.
脓毒症是由感染引起的失控反应导致的危及生命的器官功能障碍。最近的研究发现,过多的中性粒细胞胞外陷阱(NETs)有助于脓毒症的发病机制,从而增加发病率和死亡率。溶血磷脂酸(LPA)是一种小分子甘油磷脂分子,通过与其受体结合发挥多种功能。尽管已经确定 LPA 可以诱导 NETs 的产生,但 LPA 受体(特别是溶血磷脂酸受体 3(LPA3))是否以及如何在脓毒症的发展中发挥作用尚未得到探索。全面了解 LPA 对脓毒症的影响对于开发医学治疗方法至关重要。腹腔内注射脂多糖(LPS)后,与野生型(WT)小鼠相比,小鼠的死亡率显著升高,肺部损伤更严重,纤维蛋白原含量更高。凝血标志物、血浆凝血酶原时间(PT)和纤维蛋白原(FIB)的检测值表明,小鼠发生了严重的凝血过程,导致血栓形成增加。LPS 注射后,LPA3 敲除()小鼠的 NETs 水平高于 WT 小鼠。DNaseI 处理 NETs 后,脓毒症小鼠的死亡率和肺部损伤程度显著降低。此外,与单核细胞和中性粒细胞共培养的实验表明,来自 LPA3 敲除()小鼠的单核细胞促进了 NETs 的形成,这表明 LPA 作用于单核细胞可抑制 NETs 的形成,并在脓毒症中发挥保护作用。从机制上讲,我们发现 LPS 给药后小鼠单核细胞中 LPS 共受体 CD14 的表达量显著升高,Toll 样受体 4 信号下游的 MyD88-p65-NFκB 信号通路在单核细胞中过度激活。最后,给脓毒症小鼠注射 LPA 激动剂(2S)-1-油酰基-2-甲基甘油-3-磷酸胆碱(OMPT)后,改善了小鼠的存活率,减轻了器官损伤,减少了 NETs 的产生。这表明(2S)-OMPT 在治疗脓毒症方面具有潜在的转化价值和应用前景。我们的研究证实了 LPA 通过抑制 NETs 的产生和血栓形成来抑制脓毒症发展的重要保护作用,并为脓毒症治疗策略提供了新的思路。